Today: 19 April 2026
Vodafone share price steadies as buyback ticks on, with Q3 update ahead
25 January 2026
1 min read

Vodafone share price steadies as buyback ticks on, with Q3 update ahead

London, Jan 25, 2026, 09:10 GMT — Market closed.

  • Vodafone closed Friday at 104.05 pence, rising 0.4%.
  • On Friday, the group revealed a new batch of share buybacks.
  • Attention shifts to Vodafone’s trading update scheduled for Feb. 5.

Vodafone shares ended the final London session a bit up following the company’s announcement of additional share buybacks, maintaining steady backing for a stock that’s seen swings amid telecom sector news.

The stock ended Friday at 104.05 pence, gaining 0.43%. With no trading over the weekend, investors are left to consider if buybacks will continue to counterbalance ongoing concerns around pricing pressure and hefty network investments across European telecoms.

Vodafone disclosed that on Jan. 22 it acquired 2,679,550 ordinary shares at a volume-weighted average price of 103.78 pence. The shares traded between 102.20 pence and 104.70 pence. The company intends to keep these shares in treasury.

The timing is key as the wider UK market closed the week cautiously, the FTSE 100 slipping 0.07% on Friday. Investors weighed geopolitical tensions alongside a shift in risk appetite.

That backdrop keeps Vodafone’s stock volatile day-to-day: some funds treat it as a defensive pick, yet its heavy debt and network spending tie it closely to movements in rates and credit.

Fixed-line competition in the UK remains dynamic. CityFibre reported that roughly 70% of households changing broadband providers in areas covered by its network are opting for its service. Vodafone is among the retail providers offering broadband on CityFibre’s fibre footprint.

“Where CityFibre is available, we are becoming the preferred network,” CityFibre Chief Executive Simon Holden said. This bodes well for fibre adoption and ramps up the pressure on incumbents to compete on both price and speed. Reuters

Investors in Vodafone will be keeping an eye on peers connected to the same UK infrastructure — namely BT via Openreach, and Virgin Media O2 — for clues on wholesale pricing, churn rates, and how aggressively promotions are being pushed.

But buybacks aren’t a fix-all. A weaker-than-anticipated trading update, stiffer competition in crucial markets, or rising financing costs could easily overshadow any boost from repurchases.

Vodafone’s Q3 FY26 trading update lands on Feb. 5. The company will lay out how things are shaping up across its markets and either confirm or tweak guidance for the full year.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
IAG share price slips as oil jumps and Iran flight jitters return — what to watch next week
Previous Story

IAG share price slips as oil jumps and Iran flight jitters return — what to watch next week

Fresnillo PLC stock price: why Friday’s £41.68 close puts the silver miner in focus this week
Next Story

Fresnillo PLC stock price: why Friday’s £41.68 close puts the silver miner in focus this week

Go toTop